Cancer of the ovary, fallopian tube, and peritoneum (Q85015064)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22999503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

Cancer of the ovary, fallopian tube, and peritoneum (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22999503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

Jonathan S Berek

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22999503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Christopher Crum

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22999503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Michael Friedlander

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22999503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

1 October 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22999503%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Gynecology and Obstetrics

13 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22999503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

119 Suppl 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22999503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

S118-29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22999503%20AND%20SRC:MED&resulttype=core&format=json

Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

13 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

The distal fallopian tube: a new model for pelvic serous carcinogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

A genetic epidemiological study of carcinoma of the fallopian tube

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

New insights into the pathogenesis of serous ovarian cancer and its clinical impact

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Anatomy of pelvic and para-aortic nodal spread in patients with primary fallopian tube carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Carcinoma of the fallopian tube

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Symptoms associated with diagnosis of ovarian cancer: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Presenting symptoms of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Lymph node-positive stage IIIC ovarian cancer: a separate entity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Classification of human ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Calculator for ovarian carcinoma subtype prediction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

7 January 2021

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Pooled analysis of 3 european case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

ARID1A mutations in endometriosis-associated ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Effect of Screening on Ovarian Cancer Mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Conservative surgery for Stage I ovarian carcinoma in women of childbearing age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Reducing time to diagnosis does not improve outcomes for women with symptomatic ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Paclitaxel-based chemotherapy in carcinoma of the fallopian tube

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

A phase 3 trial of bevacizumab in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Incorporation of bevacizumab in the primary treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Long-term follow-up of women with ovarian cancer after positive second-look laparotomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Management of platinum-sensitive recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Oral etoposide is active against platinum-resistant epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evalu

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Current update on borderline ovarian neoplasms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Management of ovarian stromal cell tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Granulosa cell tumor of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Combination of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Testicular germ cell tumors: pathogenesis, diagnosis and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Chemotherapy for advanced germ cell tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Chemotherapy of advanced dysgerminoma: trials of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Second-look laparotomy in ovarian germ cell tumors: the gynecologic oncology group experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Treatment of malignant ovarian germ cell tumors with preservation of fertility: A report of 28 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Survival and reproductive function after treatment of malignant germ cell ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Dysgerminoma: the role of conservative surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Surveillance policy for stage I ovarian germ cell tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of mixed or non-seminomatous germ cell tumors (NSGCT)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Malignant mixed mesodermal ovarian tumor treatment and prognosis: a 20-year experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2812%2960025-3

10.1016/S0020-7292(12)60025-3

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22999503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22999503%20AND%20SRC:MED&resulttype=core&format=json